GlaxoSmithKline plc (NYSE: GSK; London), announced today that they have received a positive opinion from the European Committee for Proprietary Medicinal Products (CPMP) for Seretide (Seretide Diskus 500/50) as a new treatment for Chronic Obstructive Pulmonary Disease (COPD).
This means that European Marketing Authorization should be granted within the next few months followed by launches across Europe in the first half of 2003. “Today’s decision by the CPMP represents a milestone in the treatment of COPD – Seretide (salmeterol xinoafoate) is an effective and convenient medicine for the treatment of COPD and offers real hope to those physicians and patients fighting this deadly disease,” said Andrew Witty, President, Pharmaceuticals, Europe at GSK.
The approval is important for Europe where COPD is currently the fifth largest killer (1) and effects an estimated 340 million COPD patients worldwide (2). Seretide is the first inhaled steroid/long acting beta2 agonist combination product to receive a positive European regulatory opinion for the treatment of COPD a multi-component disease.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!